Physician profile
Mark Orgel
NPI 1902912157
$3,321.81
in general payments reported to CMS, 2019-2025
28 companies · $484 in 2025
The $484 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $272 · 2020: $141 · 2021: $538 · 2022: $406 · 2023: $813 · 2024: $668 · 2025: $484.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,965.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,965.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $578.54 | 2019-2024 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $567.27 | 2021-2025 | |
| Novo Nordisk INC | $427.05 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Abbott Laboratories | $267.65 | 2021-2025 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $251.91 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Exact Sciences Corporation | $154.97 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $151.82 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $136.49 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $132.64 | 2019-2024 | |
| Amgen INC. | $129.34 | 2019-2024 | Otezla, Repatha |
| Idorsia Pharmaceuticals US INC | $99.04 | 2022-2024 | Quviviq |
| Genentech USA, INC. | $96.61 | 2019-2022 | |
| Allergan, INC. | $63.04 | 2019-2020 | |
| Edwards Lifesciences Corporation | $28.18 | 2025 | Sapien 3 Ultra Resilia |
| Boston Scientific Corporation | $25.62 | 2025 | Spectra Wavewriter |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $22.78 | 2023 | Dexcom G6 Transmitter |
| Biohaven Pharmaceuticals, INC. | $22.67 | 2021 | |
| Jazz Pharmaceuticals INC. | $19.23 | 2019 | |
| Merck Sharp & Dohme LLC | $18.80 | 2024 | Capvaxive |
| Novartis Pharmaceuticals Corporation | $17.33 | 2022 | |
| Phathom Pharmaceuticals, INC. | $16.97 | 2024 | Voquezna |
| Astellas Pharma US INC | $16.76 | 2024 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.74 | 2023 | Xifaxan, Trulance |
| E.R. Squibb & Sons, L.L.C. | $13.49 | 2023 | Eliquis |
| Amarin Pharma, INC. | $13.28 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.70 | 2021 | |
| Currax Pharmaceuticals LLC | $11.72 | 2021 | |
| Sanofi Pasteur INC. | $11.17 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Orgel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.